Candel治疗学报告称,前列腺癌试验取得了重大成功,争取到2026年底由林业发展局批准。 Candel Therapeutics reports major success in prostate cancer trial, aiming for FDA approval by end of 2026.

Candel治疗学报告说,CAN-2409在治疗地方前列腺癌方面第3阶段试验结果是积极的,显示无病存活率提高了30%。 Candel Therapeutics reported positive phase 3 trial results for CAN-2409 in treating localized prostate cancer, showing a 30% improvement in disease-free survival. 该公司从EMA获得了FDA RMAT 前列腺癌和胰腺癌孤儿的指定。 The company received FDA RMAT designation for prostate cancer and orphan designation for pancreatic cancer from the EMA. Candel计划在Q4 2026之前提交一份《BLA》,并有足够资金在Q1 2027之前运作。 Candel plans to submit a BLA by Q4 2026 and has sufficient funds to operate until Q1 2027.